Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota history. The sale follows investor pressure on Minneapolis-based Bio-Techne, ...

Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has unanimously approved the transaction, which is now subject to regulatory review. The ...

Bio-Techne TECH reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of 56 cents, which surpassed the Zacks Consensus Estimate by 9.8%. The bottom line improved from the year-ago ...

Merck KGaA agreed to buy Bio-Techne Corporation for about $11.3 billion to bolster its life-science business, marking the German pharma and technology group’s biggest acquisition in more than a decade ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

German drugmaker Merck ​KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, its largest deal in over a decade.

We’re sorry, we are currently experiencing some issues, please try again later. Our team is working diligently to resolve the issue. Thank you for your patience and ...

According to a Feb. 17, 2026, SEC filing, Hollow Brook Wealth Management LLC sold out its entire position in Bio-Techne (NASDAQ:TECH) during the fourth quarter of 2025. The fund divested 174,677 ...